Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results , with sales up 15.7% year on year to $2.91 ...

Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.

VERX stock could present an entry point as it pulls back to its 10-week moving average. Not to be confused with Vertex Pharmaceuticals, Vertex is a company specializing in consulting services and ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

U.S. stocks end little changed on Tuesday after Fed Chair Powell rehashes last month's comments. Focus turns to inflation, ...

Vertex Pharmaceuticals fair value estimate is US$706 Vertex... To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this year ...

The new data from Vertex’s phase 1/2 trial of VX-880 ... along with becoming insulin-independent at this time point. Moreover, all 12 showed evidence that the islet cells had grafted and ...

The focus of Wall Street investors in the week ahead will be primarily on expected reciprocal trade tariffs by US President ...

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...

SpotDraft was founded in 2017 by Carnegie Mellon graduate Madhav Bhagat and Harvard Law School alumnus Shashank Bijapur with ...